Synthesis, biological activities, and molecular docking studies of triazolo[4,3‐ b ]triazine derivatives as a novel class of α‐glucosidase and α‐amylase inhibitors
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202300628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Soheila Seyfi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Glycoside Hydrolase Inhibitors, alpha-Amylases, alpha-Glucosidases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Institute for Medical Research Development, TUBITAK ULAKBIM, High Performance and Grid Computing Center.
Abstract (Originalsprache)
In diabetes mellitus, amylase and glucosidase enzymes are the primary triggers. The main function of these enzymes is to break macromolecules into simple sugar units, which directly affect blood sugar levels by increasing blood permeability. To overcome this metabolic effect, there is a need for a potent and effective inhibitor capable of suppressing the enzymatic conversion of sugar macromolecules into their smaller units. Herein, we reported the discovery of a series of substituted triazolo[4,3‐ b ][1,2,4]triazine derivatives as α‐glucosidase and α‐amylase inhibitors. All target compounds demonstrated significant inhibitory activities against α‐glucosidase and α‐amylase enzymes compared with acarbose as the positive control. The most potent compound 10k , 2‐[(6‐phenyl‐[1,2,4]triazolo[4,3‐ b ][1,2,4]triazin‐3‐yl)thio]‐ N ‐[4‐(trifluoromethyl)phenyl]acetamide, demonstrated IC 50 values of 31.87 and 24.64 nM against α‐glucosidase and α‐amylase enzymes, respectively. To study their mechanism of action, kinetic studies were also done, which determined the mode of inhibition of both enzymes. Molecular docking was used to confirm the binding interactions of the most active compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Medicinal Chemistry, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- Department of Biotechnology, Faculty of Science, Bartin University, Bartin, Turkey.
- Plant and Animal Production Department, Technical Sciences Vocational School of Sivas, Sivas Cumhuriyet University, Sivas, Turkey.
- Department of Medicinal Chemistry, School of Pharmacy, Alborz University of Medical Science, Karaj, Iran.
Förderung
- National Institute for Medical Research Development
- TUBITAK ULAKBIM
- High Performance and Grid Computing Center
- Scientific Research Project Fund of Sivas Cumhuriyet University (CUBAP)
Zitieren
APA
Seyfi, S., Salarinejad, S., Moghimi, S., Toolabi, M., Sadeghian, N., Tüzün, B., Firoozpour, L., Ketabforoosh, S. H. M. E., Taslimi, P., & Foroumadi, A. (2024). Synthesis, biological activities, and molecular docking studies of triazolo[4,3‐ b ]triazine derivatives as a novel class of α‐glucosidase and α‐amylase inhibitors. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300628
Vancouver
Seyfi S, Salarinejad S, Moghimi S, Toolabi M, Sadeghian N, Tüzün B, et al. Synthesis, biological activities, and molecular docking studies of triazolo[4,3‐ b ]triazine derivatives as a novel class of α‐glucosidase and α‐amylase inhibitors. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202300628
BibTeX
@article{Seyfi2024,
author = {Seyfi, Soheila and Salarinejad, Somayeh and Moghimi, Setareh and Toolabi, Mahsa and Sadeghian, Nastaran and Tüzün, Burak and Firoozpour, Loghman and Ketabforoosh, Shima H M E and Taslimi, Parham and Foroumadi, Alireza},
title = {Synthesis, biological activities, and molecular docking studies of triazolo[4,3‐ b ]triazine derivatives as a novel class of α‐glucosidase and α‐amylase inhibitors},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202300628}
}
EUVIMED